Cell & Gene Therapy Manufacturing Services Market

Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Cancer, Orthopedic), Application (Clinical, Commercial), End User (Pharma & Biotech, Academia) - Global Forecast to 2026

Report Code: BT 7944 Jul, 2021, by marketsandmarkets.com

[299 Pages Report] The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7 billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of this market to a certain extent.

Cell & Gene Therapy Manufacturing Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the cell & gene therapy manufacturing services market

The pandemic slowed the economic growth of various countries, including the US, Germany, the UK, India, and China. It also resulted in control measures that impacted operations in life science organizations, such as production and research. In an article published by Nature Biotechnology, the CEO of Flagship Pioneering (US) stated that lab productivity at many of its research-based setups was running at just 30–50% capacity, and even upholding that rate was a challenge.

More than 750 trials of cell & gene therapy (CGT) in almost 30,000 patients were underway as of June 2020, and CGT products account for some 12% of the pharmaceutical industry’s clinical pipeline and at least 16% of its preclinical pipeline. According to GEP Worldwide, more than 1,200 clinical trials across the globe were disrupted by June 2020. Nearly 61% of clinical trials were disrupted due to the suspension of patient enrolment. The impact varied due to changes in COVID-19 case volumes throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory disease, oncology, ID/anti-infectives, and cardiovascular disease were the worst-hit during this time.

Global Cell & gene therapy manufacturing services Market Dynamics

DRIVER: Increasing investments in pharmaceutical R&D

Most pharmaceutical companies continue to invest heavily in the development of novel drugs and devices. The pharmaceutical industry, in particular, is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. The trend suggests that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns on their investment in the long run and through collaborative R&D efforts. According to an EvaluatePharma report, the worldwide pharmaceutical R&D spending was valued at USD 136 billion in 2012; this increased to USD 186 billion in 2019. With the impact of COVID-19, the global pharma R&D growth rate has dropped to 0.3% from 2019–2020. As per report findings, this R&D spend is expected to grow steadily between 2019 and 2026 at a CAGR of 3.2% to reach USD 232.5 billion, slower than the historical CAGR of 4.6% between 2012 and 2019.

The increase in pharmaceutical R&D has resulted in a sharp increase in the number of cell & gene therapy candidates under development. This has made it necessary to outsource manufacturing services to develop cost-effective and efficient cell & gene therapies.

RESTRAINT: High operational costs associated with cell & gene therapy manufacturing

Currently, there are 1,200 cell & gene therapies in trials worldwide. There are more than 700 investigational cell & gene therapies in clinical development in the US alone. However, manufacturing facilities have not kept up. It has been estimated that hundreds of facilities will be needed to manufacture the treatments that are now in clinical trials. One of the areas that need to be accelerated is viral capacity. Most viral vectors are produced using adherent manufacturing, which is expensive to operate—a vial of 20 million cells can cost USD 20,000 to USD 30,000 to make. The cost of manufacturing for gene therapy can be between USD 500,000 and USD 1 million, excluding the costs for R&D, the costs to run crucial clinical trials, or the costs to build the commercial infrastructure necessary to provide access to patients.

OPPORTUNITY: Increasing number of cell & gene therapy clinical trials

Clinical trials are the backbone of medical research and help pharmaceutical and biopharmaceutical companies develop and commercialize new cell & gene therapies. In the past few years, the demand for clinical trials has risen worldwide as a result of the growing demand for novel medicines to fulfill unmet medical needs. According to a 2020 PhRMA report on the cell & gene therapy pipeline in 2018, there were 289 cell & gene therapies in clinical development by biopharmaceutical companies. This number increased by 25% in 2020, with 362 cell & gene therapies in clinical development. In addition to this, according to data released by CGT Catapult, there were 154 ATMP clinical trials ongoing in the UK in 2020 compared to the 127 trials reported in 2019, indicating an increase of more than 20%. This significant growth in the number of cell & gene therapy clinical trials is expected to drive the demand for manufacturing services and, in turn, propel growth in the cell & gene therapy manufacturing services market.

The cell therapy segment dominated the cell & gene therapy manufacturing services market in 2020.

On the basis of type, the cell & gene therapy manufacturing services market is broadly segmented into cell therapy and gene therapy. In 2020, cell therapy accounted for the largest share of the cell & gene therapy manufacturing services market. This can primarily be attributed to factors such as increasing awareness about cell therapy, growing funding for new cell lines, increasing partnerships and acquisitions, and the development of advanced genomics methods for cell analysis.

The pharmaceutical and biotechnology companies segment will witness the highest growth during the forecast period.

Based on application, the Cell & gene therapy manufacturing services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2020, the pharmaceutical & biotechnology companies segment is expected to register the highest CAGR during the forecast period. The high growth rate in this segment can be attributed to the increasing expenditure on R&D by pharmaceutical & biotechnology companies, rising collaborations between pharmaceutical and biotechnology companies, and the growing number of cell & gene therapies in the R&D pipeline.

Cell & Gene Therapy Manufacturing Services Market by Region

North America was the largest regional market for cell & gene therapy manufacturing services market in 2020.

Geographically, the cell & gene therapy manufacturing services market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2020, North America accounted for the largest share of the cell & gene therapy manufacturing services market, followed by Europe and the Asia Pacific. The large share of the North American market is attributed to the rising incidence of cancer and growing research activity in cancer and stem cells.

Key Market Players

Key players in the cell & gene therapy manufacturing services market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Charles River Laboratories (US), Lonza (Switzerland), Catalent (US), WuXi AppTec (China), Takara Bio Inc. (Japan), Nikon Corporation (Japan), FUJIFILM Holdings Corporation (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), Oxford Biomedica plc (UK), and Cell and Gene Therapy Catapult (UK).

Scope of the report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD Billion)

Segments covered

Type, indication, application, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Companies covered

Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Charles River Laboratories (US), Lonza (Switzerland), Catalent, Inc. (US), WuXi AppTec (China), Takara Bio Inc. (Japan), NIKON CORPORATION (Japan), FUJIFILM Holdings Corporation (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), Oxford Biomedica plc (UK), Cell and Gene Therapy Catapult (UK), The Discovery Labs LLC (US), RoslinCT (Scotland), JRS PHARMA (Germany), FinVector (Finland), ABL, Inc. (US), Resilience (US), BioCentriq (US), Porton Biopharma Limited (England), Andelyn Biosciences (US), Commercializing Living Therapies (Canada), Vibalogics (US), Anemocyte Srl (Italy), and ElevateBio (US)

This report categorizes the cell & gene therapy manufacturing services market into the following segments and subsegments:

Cell & gene therapy manufacturing services Market, by Type

  • Cell Therapy
    • Allogeneic
      • Mesenchymal Stem Cells
      • T-cells
      • Induced Pluripotent Stem Cells
      • Natural Killer Cells
      • Hematopoietic Stem Cells
      • Other Allogeneic Cells
    • Autologous
      • T-cells
      • Hematopoietic Stem Cells
      • Mesenchymal Stem Cells
      • Natural Killer Cells
    • Viral Vector
      • Retroviral Vectors
      • Adeno-associated Virus Vectors
      • Other Viral Vectors
  • Gene Therapy
    • Non-viral Vector
    • Oligonucleotides
      • Other Non-viral Vectors
    • Viral Vector
      • Retroviral Vectors
      • Adeno-associated Virus Vectors
      • Other Viral Vectors

Cell & gene therapy manufacturing services Market, by Indication

  • Oncology Diseases
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Ophthalmology Diseases
  • Central Nervous System Disorders
  • Infectious Diseases
  • Other Indications

Cell & gene therapy manufacturing services Market, by Application

  • Clinical Manufacturing
  • Commercial Manufacturing

Cell & gene therapy manufacturing services Market, by End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Other End Users

Cell & gene therapy manufacturing services Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East and Africa

Recent Developments

  • In 2021, Charles River Laboratories acquired a cell & gene therapy CDMO—Cognate BioServices—to increase its cell and gene therapy manufacturing capabilities.
  • In 2021, Thermo Fisher Scientific acquired Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for approximately USD 859.7 million. This acquisition will increase its presence in the cell & gene therapy manufacturing therapy market.
  • In 2019, Thermo Fisher Scientific acquired Brammer Bio, a company engaged in viral vector manufacturing for gene and cell therapies, for USD 1.7 billion.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 45)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED IN THE REPORT
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 49)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
           FIGURE 2 PRIMARY SOURCES
           FIGURE 3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION
           FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2020
           FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
           FIGURE 6 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: CAGR PROJECTIONS, 2021–2026
           FIGURE 7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
    2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 59)
    FIGURE 9 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 10 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
   FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET

4 PREMIUM INSIGHTS (Page No. - 63)
    4.1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET OVERVIEW
           FIGURE 14 HIGH INCIDENCE OF CANCER AND OTHER TARGET DISEASES TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE & COUNTRY (2020)
           FIGURE 15 THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
    4.3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY APPLICATION, 2020
           FIGURE 16 THE CLINICAL MANUFACTURING SEGMENT DOMINATED THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET IN 2020
    4.4 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2021–2026
           FIGURE 17 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 66)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 18 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           TABLE 1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 High incidence of cancer and other target diseases
                    5.2.1.2 Increasing investments in pharmaceutical R&D
                               FIGURE 19 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2016
                    5.2.1.3 Investments in advanced technologies by CDMOs
                    5.2.1.4 Increasing partnerships and agreements between pharmaceutical companies and CDMOs
           5.2.2 RESTRAINTS
                    5.2.2.1 High operational costs associated with cell & gene therapy manufacturing
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising demand for cell & gene therapies
                    5.2.3.2 Increasing number of cell & gene therapy clinical trials
           5.2.4 CHALLENGES
                    5.2.4.1 Risk of mutagenesis and other unwanted outcomes
           5.2.5 TRENDS
                    5.2.5.1 Expansion in emerging countries
    5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
           FIGURE 20 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SCENARIO, PRE-COVID-19 VS. POST-COVID-19 IMPACT, 2019–2021
    5.4 TECHNOLOGICAL ANALYSIS
    5.5 CASE STUDIES
           5.5.1 CGT CATAPULT PROVIDED ITS EXPERTISE IN THERAPIES DEVELOPMENT AND MANUFACTURING TO CREATE A NEW PRECLINICAL DEVELOPMENT PLAN FOR PURESPRING THERAPEUTICS’ GENE THERAPY TECHNOLOGY FOR KIDNEY DISEASES
    5.6 RANGES/SCENARIO
           FIGURE 21 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
    5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
           FIGURE 22 REVENUE SHIFT & NEW POCKETS FOR CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS
    5.8 PRICING ANALYSIS
    5.9 VALUE CHAIN ANALYSIS
           FIGURE 23 VALUE CHAIN ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: HARVESTING AND CRYOPRESERVATION PHASES ADD MAXIMUM VALUE
    5.10 ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
           FIGURE 24 ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
           TABLE 2 SUPPLY CHAIN ECOSYSTEM
    5.11 PORTER’S FIVE FORCES ANALYSIS
           TABLE 3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT FROM NEW ENTRANTS
           5.11.2 THREAT FROM SUBSTITUTES
           5.11.3 BARGAINING POWER OF BUYERS
           5.11.4 BARGAINING POWER OF SUPPLIERS
           5.11.5 INTENSITY OF COMPETITIVE RIVALRY
    5.12 REGULATORY ANALYSIS
           5.12.1 NORTH AMERICA
                    5.12.1.1 US
                    5.12.1.2 Canada
           5.12.2 EUROPE
                    5.12.2.1 Germany
                    5.12.2.2 France
                    5.12.2.3 UK
                    5.12.2.4 Rest of Europe
           5.12.3 ASIA PACIFIC
                    5.12.3.1 China
                    5.12.3.2 Japan
                    5.12.3.3 Rest of Asia Pacific
                               5.12.3.3.1 India
                               5.12.3.3.2 Australia and New Zealand
           5.12.4 LATIN AMERICA
           5.12.5 MIDDLE EAST & AFRICA
    5.13 PATENT ANALYSIS
           FIGURE 25 NUMBER OF PATENT APPLICATIONS FILED FOR CELL & GENE THERAPY MANUFACTURING SERVICES, JANUARY 2010–DECEMBER 2020

6 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE (Page No. - 83)
    6.1 INTRODUCTION
           TABLE 4 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
    6.2 CELL THERAPY
           TABLE 5 CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 6 CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 7 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 8 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 9 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.1 ALLOGENEIC
                    TABLE 10 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 11 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 12 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 13 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 14 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.1 Mesenchymal stem cells
                               6.2.1.1.1 MSCs are ideal for cell therapy because of their immunosuppressive and tissue repair properties
                                            TABLE 15 ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 16 NORTH AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 17 EUROPE: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 18 ASIA PACIFIC: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.2 T-cells
                               6.2.1.2.1 Allogeneic T-Cells are immediately available because of cryopreserved batches
                                            TABLE 19 ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 20 NORTH AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 21 EUROPE: ALLOGENEIC T-CELLS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 22 ASIA PACIFIC: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.3 Induced pluripotent stem cells
                               6.2.1.3.1 Growing adoption Of IPSCs in research to drive market growth
                                            TABLE 23 ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 24 NORTH AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 25 EUROPE: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 26 ASIA PACIFIC: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.4 Natural killer cells
                               6.2.1.4.1 Allogeneic natural killer cell therapies are used for advanced hepatocellular carcinoma patients
                                            TABLE 27 ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 28 NORTH AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 29 EUROPE: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 30 ASIA PACIFIC: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.5 Hematopoietic stem cells
                               6.2.1.5.1 Stem cells from a donor are used for allogeneic transplantation
                                            TABLE 31 ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 32 NORTH AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 33 EUROPE: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 34 ASIA PACIFIC: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.1.6 Other allogeneic cells
                               TABLE 35 OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 36 NORTH AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 37 EUROPE: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 38 ASIA PACIFIC: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.2 AUTOLOGOUS
                    TABLE 39 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 40 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 41 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 42 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 43 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.2.1 T-cells
                               6.2.2.1.1 T-cells are major components of the adaptive immune system
                                            TABLE 44 AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 45 NORTH AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 46 EUROPE: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 47 ASIA PACIFIC: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.2.2 Hematopoietic stem cells
                               6.2.2.2.1 Hematopoietic stem cells are used to establish marrow and bone function
                                            TABLE 48 AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 49 NORTH AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 50 EUROPE: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 51 ASIA PACIFIC: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.2.3 Mesenchymal stem cells
                               6.2.2.3.1 Mesenchymal stem cells are present in the umbilical cord, bone marrow, & fat tissue
                                            TABLE 52 AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 53 NORTH AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 54 EUROPE: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 55 ASIA PACIFIC: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.2.4 Natural killer cells
                               6.2.2.4.1 NK Cells are used in the treatment of tumors and infectious diseases
                                            TABLE 56 AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 57 NORTH AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 58 EUROPE: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 59 ASIA PACIFIC: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.2.5 Other autologous cells
                               TABLE 60 OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 61 NORTH AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 62 EUROPE: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 63 ASIA PACIFIC: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.2.3 VIRAL VECTOR
                    TABLE 64 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 65 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 66 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 67 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.3.1 Retroviral vectors
                               6.2.3.1.1 Retroviral vectors are the most used viral vectors for cell therapy manufacturing
                                            TABLE 69 RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 70 NORTH AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 71 EUROPE: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 72 ASIA PACIFIC: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.3.2 Adeno-associated virus vectors
                               6.2.3.2.1 AAV vector-based techniques are used for car-t cell therapy development
                                            TABLE 73 ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 74 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 75 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 76 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.2.3.3 Other viral vectors
                               TABLE 77 OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 78 NORTH AMERICA: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 79 EUROPE: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 80 ASIA PACIFIC: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 GENE THERAPY
           TABLE 81 GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
           TABLE 82 GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 83 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 84 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 85 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.1 NON-VIRAL VECTORS
                    TABLE 86 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 87 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 88 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 89 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 90 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.1.1 Oligonucleotides
                               6.3.1.1.1 North America accounted for the largest share of the oligonucleotides market
                                            TABLE 91 OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 92 NORTH AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 93 EUROPE: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 94 ASIA PACIFIC: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.1.2 Other non-viral vectors
                               TABLE 95 OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 96 NORTH AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 97 EUROPE: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 98 ASIA PACIFIC: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.2 VIRAL VECTORS
                    TABLE 99 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 100 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 101 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 102 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 103 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.1 Retroviral vectors
                               6.3.2.1.1 Retroviral vectors possess the ability to replicate within a cell
                                            TABLE 104 RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 105 NORTH AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 106 EUROPE: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 107 ASIA PACIFIC: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.2 Adeno-associated virus vectors
                               6.3.2.2.1 Adeno-associated virus vectors have low toxicity
                                            TABLE 108 ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                            TABLE 109 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 110 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                            TABLE 111 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.3 Other viral vectors
                               TABLE 112 OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 113 NORTH AMERICA: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 114 EUROPE: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 115 ASIA PACIFIC: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION (Page No. - 131)
    7.1 INTRODUCTION
           TABLE 116 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
    7.2 ONCOLOGY DISEASES
           7.2.1 THE DEMAND FOR CELL & GENE THERAPIES IS INCREASING WITH THE RISING NUMBER OF CANCER CASES WORLDWIDE
                    TABLE 117 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 118 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 119 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 120 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 CARDIOVASCULAR DISEASES
           7.3.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES DRIVES THE MARKET GROWTH
                    TABLE 121 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 122 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 123 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 124 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 ORTHOPEDIC DISEASES
           7.4.1 CELL THERAPY FOR ORTHOPEDIC DISEASES ELIMINATES POST-TREATMENT COMPLICATIONS
                    TABLE 125 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 126 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 127 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 128 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    7.5 OPTHALMOLOGY DISEASES
           7.5.1 STEM CELL THERAPIES CAN BE USED FOR THE RESTORATION & PRESERVATION OF VISION; KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 129 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 130 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 131 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 132 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    7.6 CENTRAL NERVOUS SYSTEM DISORDERS
           7.6.1 INCREASING INCIDENCE OF SPINAL MUSCULAR ATROPHY SUPPORTS THE MARKET GROWTH
                    TABLE 133 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 134 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 135 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 136 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
    7.7 INFECTIOUS DISEASES
           7.7.1 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE THE MARKET GROWTH OF THIS SEGMENT
                    TABLE 137 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 138 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 139 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 140 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    7.8 OTHER INDICATIONS
           TABLE 141 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 142 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 143 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 144 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

8 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION (Page No. - 145)
    8.1 INTRODUCTION
           TABLE 145 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    8.2 CLINICAL MANUFACTURING
           8.2.1 THE RISING NUMBER OF CLINICAL TRIALS FOR CELL & GENE THERAPIES IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 146 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 147 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 148 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 149 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 COMMERCIAL MANUFACTURING
           8.3.1 MARKET GROWTH CAN BE ATTRIBUTED TO THE INCREASING APPROVALS OF CELL & GENE THERAPY PRODUCTS FOR COMMERCIAL MANUFACTURING
                    TABLE 150 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 151 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 152 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 153 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)

9 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER (Page No. - 150)
    9.1 INTRODUCTION
           TABLE 154 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           9.2.1 GROWING NUMBER OF CELL & GENE THERAPIES IN THE R&D PIPELINE TO DRIVE THE MARKET GROWTH
                    TABLE 155 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 156 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 157 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 158 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 ACADEMIC & RESEARCH INSTITUTES
           9.3.1 INCREASE IN LIFE SCIENCES R&D EXPENDITURE TO CONTRIBUTE TO THE GROWTH OF THIS SEGMENT
                    TABLE 159 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 160 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 161 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 162 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 OTHER END USERS
           TABLE 163 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 164 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 165 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 166 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)

10 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION (Page No. - 158)
     10.1 INTRODUCTION
             TABLE 167 CELL & GENE THERAPY MANUFACTURING THERAPY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 26 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT
             TABLE 168 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 169 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 170 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 171 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 172 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 173 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 174 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
             TABLE 175 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 176 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 177 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
             TABLE 178 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 179 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Growing focus on cancer research in the US will drive market growth
                                     TABLE 180 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 181 US: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 182 US: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 183 US: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 184 US: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 185 US: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                                     TABLE 186 US: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 187 US: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 188 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                                     TABLE 189 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 190 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Growth in Canada can be attributed to the rising funding for stem cell research in the country
                                     TABLE 191 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 192 CANADA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 193 CANADA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 194 CANADA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 195 CANADA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 196 CANADA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                                     TABLE 197 CANADA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 198 CANADA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 199 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                                     TABLE 200 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 201 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.3 EUROPE
             TABLE 202 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 203 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 204 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 205 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 206 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 207 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 208 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
             TABLE 209 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 210 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 211 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
             TABLE 212 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 213 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth
                                     TABLE 214 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 215 GERMANY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 216 GERMANY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 217 GERMANY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 218 GERMANY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 219 GERMANY: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                                     TABLE 220 GERMANY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 221 GERMANY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 222 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                                     TABLE 223 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 224 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth
                                     TABLE 225 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 226 UK: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 227 UK: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 228 UK: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 229 UK: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 230 UK: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                                     TABLE 231 UK: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 232 UK: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 233 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                                     TABLE 234 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 235 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Growth can be attributed to rising government funding for cancer research
                                     TABLE 236 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 237 FRANCE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 238 FRANCE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 239 FRANCE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 240 FRANCE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 241 FRANCE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                                     TABLE 242 FRANCE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 243 FRANCE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 244 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                                     TABLE 245 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 246 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.4 REST OF EUROPE
                        TABLE 247 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 248 ROE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 249 ROE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 250 ROE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 251 ROE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 252 ROE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                        TABLE 253 ROE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 254 ROE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 255 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                        TABLE 256 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 257 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 27 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT
             TABLE 258 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 259 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 260 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 261 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 262 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 263 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 264 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
             TABLE 265 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 266 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 267 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
             TABLE 268 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 269 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 The growing pharmaceutical industry and rising number of CDMOs in the country will drive market growth
                                     TABLE 270 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 271 CHINA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 272 CHINA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 273 CHINA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 274 CHINA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 275 CHINA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                                     TABLE 276 CHINA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 277 CHINA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 278 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                                     TABLE 279 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 280 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Research collaborations and growing geriatric population—key growth drivers in Japan
                                     TABLE 281 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 282 JAPAN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 283 JAPAN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 284 JAPAN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 285 JAPAN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 286 JAPAN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                                     TABLE 287 JAPAN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 288 JAPAN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 289 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                                     TABLE 290 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 291 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.3 REST OF ASIA PACIFIC
                        TABLE 292 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 293 ROAPAC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 294 ROAPAC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 295 ROAPAC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 296 ROAPAC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 297 ROAPAC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                        TABLE 298 ROAPAC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 299 ROAPAC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 300 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                        TABLE 301 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 302 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET
                        TABLE 303 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 304 LATAM: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 305 LATAM: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 306 LATAM: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 307 LATAM: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 308 LATAM: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                        TABLE 309 LATAM: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 310 LATAM: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 311 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                        TABLE 312 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 313 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D
                        TABLE 314 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 315 MEA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 316 MEA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 317 MEA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 318 MEA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 319 MEA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
                        TABLE 320 MEA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 321 MEA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 322 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
                        TABLE 323 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 324 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 220)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             FIGURE 28 KEY PLAYER STRATEGIES IN THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, 2018–2021
     11.3 MARKET SHARE ANALYSIS
             FIGURE 29 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 30 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 EMERGING COMPANIES
           FIGURE 31 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2020
     11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 32 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
     11.7 SERVICE FOOTPRINT OF COMPANIES
             TABLE 325 SERVICE PORTFOLIO ANALYSIS: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020)
     11.8 REGIONAL FOOTPRINT OF COMPANIES
             TABLE 326 REGIONAL FOOTPRINT OF COMPANIES: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020)
     11.9 COMPETITIVE SCENARIO
             TABLE 327 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DEALS, JANUARY 2018–JUNE 2021
             TABLE 328 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2018 –JUNE 2021

12 COMPANY PROFILES (Page No. - 232)
     12.1 KEY MARKET PLAYERS
(Business Overview, Services Offered, Recent Developments, and MnM View)* 
             12.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 329 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
             12.1.2 MERCK KGAA
                        TABLE 330 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2020)
             12.1.3 CHARLES RIVER LABORATORIES
                        TABLE 331 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 35 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
             12.1.4 LONZA
                        TABLE 332 LONZA: BUSINESS OVERVIEW
                        FIGURE 36 LONZA: COMPANY SNAPSHOT (2020)
             12.1.5 CATALENT, INC.
                        TABLE 333 CATALENT, INC.: BUSINESS OVERVIEW
                        FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2020)
             12.1.6 TAKARA BIO INC.
                        TABLE 334 TAKARA BIO INC.: BUSINESS OVERVIEW
                        FIGURE 38 TAKARA BIO INC.: COMPANY SNAPSHOT (2020)
             12.1.7 OXFORD BIOMEDICA PLC
                        TABLE 335 OXFORD BIOMEDICA PLC: BUSINESS OVERVIEW
                        FIGURE 39 OXFORD BIOMEDICA PLC: COMPANY SNAPSHOT (2020)
             12.1.8 CELL AND GENE THERAPY CATAPULT
                        TABLE 336 CELL AND GENE THERAPY CATAPULT: BUSINESS OVERVIEW
                        FIGURE 40 CELL AND GENE THERAPY CATAPULT: COMPANY SNAPSHOT (2020)
             12.1.9 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 337 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
             12.1.10 FUJIFILM HOLDINGS CORPORATION
                        TABLE 338 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 42 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.11 WUXI APPTEC
                        TABLE 339 WUXI APPTEC: BUSINESS OVERVIEW
                        FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2020)
             12.1.12 NIKON CORPORATION
                        TABLE 340 NIKON CORPORATION: BUSINESS OVERVIEW
                        FIGURE 44 NIKON CORPORATION: COMPANY SNAPSHOT (2020)
     12.2 OTHER PLAYERS
             12.2.1 THE DISCOVERY LABS LLC
                        TABLE 341 THE DISCOVERY LABS LLC: BUSINESS OVERVIEW
             12.2.2 ROSLINCT
                        TABLE 342 ROSLINCT: BUSINESS OVERVIEW
             12.2.3 JRS PHARMA
                        TABLE 343 JRS PHARMA: BUSINESS OVERVIEW
             12.2.4 FINVECTOR
                        TABLE 344 FINVECTOR: BUSINESS OVERVIEW
             12.2.5 ABL, INC.
                        TABLE 345 ABL, INC.: BUSINESS OVERVIEW
             12.2.6 RESILIENCE, INC.
                        TABLE 346 RESILIENCE, INC.: BUSINESS OVERVIEW
             12.2.7 BIOCENTRIQ
                        TABLE 347 BIOCENTRIQ: BUSINESS OVERVIEW
             12.2.8 PORTON BIOPHARMA LIMITED
                        TABLE 348 PORTON BIOPHARMA LIMITED: BUSINESS OVERVIEW
             12.2.9 ANDELYN BIOSCIENCES
             12.2.10 COMMERCIALIZING LIVING THERAPIES
             12.2.11 VIBALOGICS
             12.2.12 ANEMOCYTE SRL
             12.2.13 ELEVATE BIO
* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 289)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the cell & gene therapy manufacturing services market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell & gene therapy manufacturing services market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include the American Society of Gene & Cell Therapy (ASGCT), Centers for Disease Control and Prevention (CDC), GLOBOCAN, World Health Organization (WHO), US Food and Drug Administration (FDA), National Institutes of Health (NIH), European Union (EU), National Stem Cell Foundation, International Society for Cell & Gene Therapy (ISCT), EuroStemCell, European Society of Gene and Cell Therapy, Japan Human Cell Society, Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), and European Federation of Pharmaceutical Industries and Associations (EFPIA). These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Cell & Gene Therapy Manufacturing Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell & gene therapy manufacturing services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the cell & gene therapy manufacturing services business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global cell & gene therapy manufacturing services market based on the type, indication, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities, and trends)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cell & gene therapy manufacturing services market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the cell & gene therapy manufacturing services market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

An additional five company profiles

COVID-19

Get in-depth analysis of the COVID-19 impact on the Cell & Gene Therapy Manufacturing Services Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Cell & Gene Therapy Manufacturing Services Market

Request For Special Pricing
Report Code
BT 7944
Published ON
Jul, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cell & Gene Therapy Manufacturing Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home